ArticleAdvanced healthcare materials2026
Stem Cell-Derived Mitochondria-Enriched Preservation Solutions as Organelle-Based Therapeutic Strategy for Cold Storage of Liver and Kidney.
Article in Advanced healthcare materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Organ preservation remains a critical challenge in transplantation, primarily due to hypothermia-induced oxidative stress and metabolic dysfunction. Here, we report a mitochondria-enriched, cell-free preservation strategy by supplementing standard preservation solutions with freshly isolated mitochondria derived from human induced pluripotent stem cell-mesenchymal stem cells (MSC-mt). MSC-mt retained intact ultrastructure and functional biophysical properties. In vitro, MSC-mt were internalized by hepatocyte- and kidney-derived cells, reduced oxidative stress, preserved ATP levels, and attenuated apoptosis under cold stress. Ex vivo, MSC-mt improved liver preservation in University of Wisconsin (UW) solution, reducing sinusoidal edema, apoptosis, ALT/AST release, MDA accumulation, and oxidative DNA damage while enhancing SOD activity and preserving mitochondrial content. Human-specific mitochondrial signals remained detectable within preserved hepatic tissue. In a warm reoxygenation model, MSC-mt enhanced ATP recovery and reduced tissue injury and oxidative damage following cold storage. In kidneys, MSC-mt provided stronger protection than fibroblast- or adipose-derived mitochondria across both HC-A and UW solutions. Mechanistically, MSC-mt showed higher total and phosphorylated PINK1 levels and greater Parkin co-localization than fibroblast-derived mitochondria, while mitophagy inhibition partially reversed their antioxidant effects. These findings establish MSC-mt as a cell-free mitochondrial strategy for improving hypothermic organ preservation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.